Sartorius Stedim Biotech S.A. (EPA:DIM)
France · Delayed Price · Currency is EUR 203.90
+17.95 (9.65%)
Oct 16, 2025, 5:35 PM CET
Sartorius Stedim Biotech Revenue
Sartorius Stedim Biotech had revenue of 705.70M EUR in the quarter ending September 30, 2025, with 7.67% growth. This brings the company's revenue in the last twelve months to 2.95B, up 7.72% year-over-year. In the year 2024, Sartorius Stedim Biotech had annual revenue of 2.78B with 0.16% growth.
Revenue (ttm)
2.95B
Revenue Growth
+7.72%
P/S Ratio
6.73
Revenue / Employee
293.78K
Employees
9,901
Market Cap
19.84B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.78B | 4.50M | 0.16% |
| Dec 31, 2023 | 2.78B | -717.20M | -20.53% |
| Dec 31, 2022 | 3.49B | 605.70M | 20.98% |
| Dec 31, 2021 | 2.89B | 976.92M | 51.15% |
| Dec 31, 2020 | 1.91B | 469.51M | 32.59% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EssilorLuxottica Société anonyme | 27.24B |
| Sanofi | 45.74B |
| bioMérieux | 4.12B |
| Eurofins Scientific SE | 7.14B |
| Ipsen | 3.76B |
| ABIVAX Société Anonyme | 6.02M |
| Virbac | 1.43B |
| emeis Société anonyme | 5.77B |
Sartorius Stedim Biotech News
- 4 hours ago - Q3 2025 Sartorius AG and Sartorius Stedim Biotech SA Earnings Call Transcript - GuruFocus
- 11 hours ago - Sartorius Stedim (SDMHF) Reports Strong Q3 Earnings and Updates Guidance - GuruFocus
- 13 hours ago - Sartorius Stedim Biotech Non-GAAP EPS of €0.94, revenue of €705.7M; raises FY outlook - Seeking Alpha
- 14 hours ago - Sartorius Stedim Biotech Earnings Up In H1; Lifts FY25 Outlook - Nasdaq
- 2 months ago - Sartorius Stedim Biotech and Nanotein Technologies Partner to Advance Cell Therapy Manufacturing - Business Wire
- 2 months ago - Bio Usawa Biotechnology and Sartorius Stedim Biotech Forge Partnership to Pioneer Biopharmaceutical Manufacturing in Africa - GlobeNewsWire
- 3 months ago - Sartorius Stedim Biotech and Sensible Biotechnologies Partner to Scale Up Sensible's Unique Cell-Based mRNA Design and Manufacturing Platform - Business Wire
- 9 months ago - Sartorius Stedim Biotech SA (SDMHF) Q4 2024 Earnings Call Highlights: Navigating Growth Amid ... - GuruFocus